Skip to main content

Policy Issues in Nanotechnology and Oncology: A Workshop

Completed

Nanotechnology holds promise for cancer screening, chemotherapy, cancer diagnosis, and the creation of combination products such as theranostics. Significant research funding is currently devoted to research in nanomedicine, providing opportunities for scientific advances and new products. Even so, there are substantial challenges to overcome in clinical research as well as translational science hurdles. The goal of the workshop was to describe nanomedicine and its potential risks and benefits, and well as to discuss the current state of standards and regulation for nanomedicine in oncology.

Description

The National Cancer Policy Forum intends to sponsor a public workshop addressing issues related to two potential foci:
1) Implementation of a regulatory framework around nanomedicine: internationalization, harmonization, and safety, including topics such as
a. Government-led initiatives
b. International initiatives
c. Manufacturer intellectual property, competitiveness, and public safety concerns
d. Perspectives from other countries
2) Issues and implications for nanomedicine: translational science and clinical research, including topics such as
a. Government-led initiatives
b. Challenges of interdisciplinary collaboration
c. Need for clinical researcher, clinicians, and public understanding of risks and benefits of nanomedicine.
An ad hoc committee will plan and conduct the workshop, which may include presentations and discussion on: introduction to nanotechnology and nanomedicine, in addition to sessions relevant to the foci listed above. The workshop which is to be held at an open meeting of the Forum on July 12th and 13th, 2010, will feature invited presentations and discussion and will serve to inform the Forum. An individually-authored summary of the workshop will subsequently be prepared by a designated rapporteur.

Contributors

Sponsors

American Association for Cancer Research

American Cancer Society

American Society of Clinical Oncology

Association of American Cancer Institutes

C-Change

Centers for Disease Control and Prevention (CDC)

CEO Roundtable on Cancer

National Cancer Institute

Novartis Oncology

Oncology Nursing Society

Staff

Christine Micheel

Lead

Sharyl Nass

Lead

Erin Balogh

Lead

Patrick Burke

Subscribe to Email from the National Academies
Keep up with all of the activities, publications, and events by subscribing to free updates by email.